期刊文献+

阿卡波糖联合其他降糖药物治疗糖尿病的临床疗效进展 被引量:3

The Clinical Efficacy of Acarbose in Combination with Other Antidiabetic Drugs for the Treatment of Diabetes
下载PDF
导出
摘要 目的探讨观察阿卡波糖联合其他降糖药物治疗糖尿病的临床疗效及进展情况。方法选取2016年5月—2017年12月期间该院收治的180例糖尿病患者,对其进行随机分组,联合治疗组和对照组,各组均为90例患者,其中为对照组患者针对应用各种其他降糖药物治疗,而联合治疗组则在此基础上联合给予阿卡波糖(于每日三餐前口服50~100 mg)治疗,观察对比两组糖尿病患者的临床降糖效果。结果治疗后,两组患者的空腹血糖和餐后2 h血糖值均较治疗前有明显性下降,但经统计学组间比较,治疗后的联合治疗组患者的降糖效果更优于对照组,差异有统计学意义(P<0.05)。而且在降糖治疗过程中,联合治疗组患者的低血糖发生率及药物用量均明显低于对照组,差异有统计学意义(P<0.05)。结论阿卡波糖联合其他降糖药物治疗糖尿病的临床疗效更为显著,可明显缩短糖尿病患者的血糖达标时间,有效降低治疗期间发生的低血糖事件,且可降低相关药物的实际用量,具有更高的用药安全性,值得临床中进一步研究其药物联合应用方案及疗效进展。 Objective To the investigate the clinical efficacy and progress of observation of acarbose combined with other antidiabetic drugs for the treatment of diabetes. Methods 180 patients with diabetes from May 2016 to December2017 were randomly divided into two groups, combined treatment group and control group, all of which were 90 patients. The control group was treated with all kinds of other hypoglycemic drugs, and the combined treatment group was combined with acarbose(Yu Mei) on this basis. 3 days before meals, oral 50-100 mg treatment was used to observe and compare the clinical hypoglycemic effect of two groups of diabetic patients. Results After treatment, the fasting blood glucose and postprandial 2 h blood sugar of the two groups were significantly lower than those before the treatment, but the effect of the combined treatment group was better than that of the control group after the treatment, and the difference level was statistically significant(P〈0.05). Moreover, during hypoglycemic treatment, the incidence of hypoglycemia and drug dosage in the combined treatment group were significantly lower than those in the control group, with statistical significance(P〈0.05). Conclusion Acarbose combined with other hypoglycemic drugs is more effective in the treatment of diabetes. It can obviously shorten the time of blood sugar in diabetic patients,effectively reduce the hypoglycemia events in the period of treatment, and reduce the actual dosage of the related drugs, which has a higher drug safety. It is worth further study of the drug in the clinic. Combined application and therapeutic effect.
作者 依巴代提古丽.艾买提 热依拉.阿布力克木 Ib adatiguri ·A mat;Ge ira · Ablickwood(Department of Pharmacy,First People's Hospital,Kashi,Xinjiang,844000 Chin)
出处 《糖尿病新世界》 2018年第4期9-10,共2页 Diabetes New World Magazine
关键词 阿卡波糖 降糖药物 糖尿病 Aearbose Hypoglyeemic drugs Diabetes
  • 相关文献

二级参考文献60

  • 1Huang Z, Wan X, Liu J, et al.Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant tx-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus[J].Diabetes Technol Ther,2013,15(10):859-869. 被引量:1
  • 2Wang JS, Huang CN, Hung YJ, et al.Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes[J].Diabetes Res Clin Pract, 2013,102(1):16-24. 被引量:1
  • 3Nakhaee A, Sanjari M.Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman[J].J Res Med Sci. 2013,18(5):391- 394. 被引量:1
  • 4Zheng F, Yin X, Lu W, et al.Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients[J].J Endocrinol Invest,2013,36(7):489-496. 被引量:1
  • 5Zhu Q, Tong Y, Wu T, et al. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis[J].Clin Ther,2013,35(6):880-899. 被引量:1
  • 6Smith-Marsh D.Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance[J].Drugs Today(Barc),2013,49(8):499-507. 被引量:1
  • 7Shihabi AR, Moussa EM, Sobierajska H, et al.An observational study of acarbose treatment in patients with type 2 diabetes from the Middle East and Morocco[J]. Diabetes Metab Syndr Obes,2013,9(6):141-150. 被引量:1
  • 8Yang G, Li C, Gong Y,A prospective, randomized, open- label study comparing the efficacy and safety of preprandialand prandial insulin in combination with acarbose in elderly, insulin-requiring patients with type 2 diabetes mellitus [J].Diabetes Technol Ther,2013,15(6):513-519. 被引量:1
  • 9Zhou J, Li H, Zhang X, Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes[J].Diabetes Technol Ther,2013,15(6):481-488. 被引量:1
  • 10Wu QL, Liu YP, Lu JM, et al.Efficacy and safety of acarbose chewable tablet in patients with type 2 diabetes: a multicentre, randomized, double-blinded, double-dummy positive controlled trial[J].J Evid Based Med,2012,5(3):134- 138. 被引量:1

共引文献66

同被引文献59

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部